研究開発基本方針 | 研究開発 | 生化学工業株式会社

This page outlines Biochem Pharma's R&D fundamental policy. The company leverages advanced carbohydrate science to develop innovative pharmaceuticals addressing unmet medical needs. Key pipeline products include SI-6603 for lumbar disc herniation in the US, targeting FDA approval; SI-449 for adhesion prevention in Japan, planned for 2026 submission; and Gel-One for knee and hip osteoarthritis in Japan. The company focuses on glycosaminoglycans (GAG), accumulating 70+ years of research expertise. R&D emphasizes orthopedic and ophthalmologic disease areas, with expanded focus on emerging fields. Innovative research integrating novel modalities shows progress, supporting global product delivery and pipeline enrichment to serve more patients.